MAPT and Alzheimer disease: TFEB activation promotes clearance of Aβ and tau pathology in preclinical models of AD (Akwa et al., 2023; Martini-Stoica et al., 2018; Polito et al., 2014; Song et al., 2020; Xiao et al., 2015; Xu et al., 2020), where TRPML1 activation has been shown to be essential for TFEB-mediated clearance of tau-induced pathology (Xu et al., 2020).